EGFR and non-small cell lung carcinoma: Alterations including KRAS, EGFR, STK11 (Serine/Threonine Kinase 11), KEAP1 (Kelch-like ECH-associated protein 1), and MDM2 (Mouse double minute 2 homolog), among others, may impact immunotherapy sensitivity and outcomes in NSCLC [63].